Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal
Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Efavirenz (Drug); Lamivudine/zidovudine (Drug)
Phase: N/A
Status: Completed
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s): Souleymane Mboup, PharmD, Study Chair, Affiliation: Laboratoire de Bacteriologic et de Virologie, Hospital Le Dantec Avenue Pasteur
Summary
The purpose of this study is to determine the safety and effectiveness of the anti-HIV drugs
efavirenz and lamivudine/zidovudine given to treatment-naive HIV-infected people in Dakar,
Senegal.
Clinical Details
Official title: A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Virologic efficacy, defined as HIV-1 viral load less than 200 copies/mlTreatment-related toxicity of Grade 3 or higher as measured by development of drug-related toxicities severe enough to warrant dose modification, interruption, or permanent discontinuation
Secondary outcome: Virologic efficacyTreatment related toxicity Virologic failure, defined as HIV-1 viral load greater than 1,000 copies/ml CD4 counts and HIV-1 RNA viral load First new or recurrent AIDS-defining event (as defined by the CDC Expanded AIDS Surveillance Case definition) or death Treatment discontinuation, defined as premature discontinuation of participation in the study, failure to take ARV therapy for 8 or more consecutive weeks, or to switch to another ARV regimen for any reason during the full course of the study Genotypic resistance measured by at least 1 genotypic mutation associated with resistance among subjects with a confirmed virologic failure (as described previously) and evaluation of genotypic drug resistance patterns Treatment adherence, defined by 95% or greater of prescribed pills taken Quality of life as measured by items and patterns of responses to the FAHI questionnaire HIV-1 DNA and RNA measurements
Detailed description:
Despite a relatively low prevalence of HIV infection, all HIV subtypes have been documented
in Senegal. Data on mutations that confer resistance to antiretroviral (ARV) drugs are
limited to HIV subtype B; adherence data are also limited. The study will evaluate the
safety and efficacy of an ARV regimen given to treatment-naive HIV infected adults and
adolescents. The study will also examine the characteristics of virologic failure and
adherence in this treatment group. Participants will be recruited at two sites in Dakar,
Senegal.
This study will last 96 weeks. At study entry, all participants will be given an ARV regimen
of lamivudine/zidovudine twice daily and efavirenz once daily. If toxicity or treatment
failure occurs, some participants may require changes in their ARV regimens. There will be
14 study visits during the study; a physical exam, blood collection, and sociodemographic
and medication history assessments will occur at each visit. Participants will also be asked
to complete quality-of-life and adherence questionnaires. An off-study visit will occur at
approximately one month after Week 96, with assessments and procedures similar to visits
during the study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- HIV-infected
- Have never taken ARV drugs
- CD4 count of 200 cells/mm3 or less within 30 days of study entry if asymptomatic OR
CD4 count of 350 cells/mm3 or less within 60 days of study entry if CDC Category A or
B clinical condition present OR clinical diagnosis of AIDS, regardless of CD4 count
- Willing to stay in the study area for the duration of the study
- Willing to use acceptable forms of contraception
Exclusion Criteria:
- HIV-2 infected
- Systemic chemotherapy (except interferon) within 6 months prior to study entry
- Current drug or alcohol abuse that, in the opinion of the investigator, may interfere
with the study
- Serious illness, including any active AIDS-defining infection, active tuberculosis,
malaria, or any illness requiring systemic treatment or hospitalization. People who
have completed therapy or are clinically stable on therapy for at least 14 days prior
to study entry are not excluded.
- Serious psychiatric problems within 60 days of study entry, including depression,
suicidal thoughts or attempts, aggressive behavior, or psychosis-like symptoms
- Have taken certain medications within 30 days of study entry
- Pregnancy or breastfeeding
Locations and Contacts
Centre National Hospitalier de Fann, Dakar CIPRA CRS, Dakar, Senegal
Institut d'Hygiène Sociale, Dakar CIPRA CRS, Dakar, Senegal
Additional Information
Click here for more information on efavirenz Click here for more information on lamivudine/zidovudine Click here for more information on HIV regimen failure Click here for more information on changing regimens Click here for more information on adherence Click here for more information on adhering to a regimen Haga clic aquí para ver información sobre este ensayo clínico en español.
Related publications: Meda N, Ndoye I, M'Boup S, Wade A, Ndiaye S, Niang C, Sarr F, Diop I, Caraël M. Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention? AIDS. 1999 Jul 30;13(11):1397-405. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR; CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004 Oct 1;39(7):1038-46. Epub 2004 Sep 10.
Starting date: July 2006
Last updated: September 4, 2013
|